
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is an up and coming company with a promising pipeline of clinical-stage product candidates. Its recently announced positive data on its lead asset, darovasertib, for metastatic uveal melanoma has de-risked potential future readouts and increased the potential market size for the drug. Additionally, the company's synthetic lethality platform has shown early clinical success and provides additional opportunities for revenue. However, as with any other biotechnology company, there are risks associated with R&D, regulatory setbacks, and competition, which could impact the company's future success.
Bears say
IDEAYA Biosciences is an oncology-focused precision medicine company that has six clinical-stage product candidates and multiple preclinical programs in development. However, its safety and tolerability profile for its main drug combination, darovasertib and crizo, has been underwhelming with most common Grade 3+ adverse events including diarrhea and syncope. Additionally, their valuation for 2030, based on discounted sales projections, is high and dependent on the success of their pipeline programs, which have yet to be clearly defined.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares